“Scientists discover Easter Island ‘fountain of youth’ drug that can extend life by 10 years,” a recent newspaper headline read.
“Coffee may ‘reverse’ Alzheimer’s,” another said.
Amazing and shocking stuff, but there’s a caveat — the research that fueled the stories was done on mice.
Mus musculus is the creature most experimented on in the history of humanity and you can bet that any modern pharmaceutical medical treatment or basic understanding of genetics has involved working on a mouse at some point. Approximately 85 percent of all animals used in experiments are rodents and the vast majority of those are mice.
And for good reason.
“Mice are used because they’re the smallest and one of the easiest mammals to study in a laboratory setting — they breed quickly and are good enough for many types of study,” says Simon Festing, chief executive of the UK pro-research charity Understanding Animal Research.
“While there are differences, we know that the main biological body systems work in the same way in all mammals. The reproductive, endocrine and cardiovascular and the central nervous systems all have a very similar structure and function,” he says. “Mice share over 90 percent of their genes with humans.”
However, using a mouse can never tell scientists everything they need to know. A result on a mouse is an interesting lead but only replication in a higher animal, such as a dog or a monkey, pushes it closer to becoming a reality for people. In the case of the Easter Island elixir (a drug called rapamycin), reports suggested that the anti-aging pill made from chemicals found on the islands had extended the life of mice by up to 38 percent — but the researchers warned that humans should not think about using the drug to extend life because it suppresses immunity.
And the Alzheimer’s study, published in the Journal of Alzheimer’s Disease, showed that caffeine could slow down the build-up of protein plaques, which are the signature of the disease and cause the damage to the brain. The mice were given the equivalent of five cups of coffee per day, containing around 500mg of caffeine, and showed almost a 50 percent reduction in the levels of the protein plaques in their brains after two months. But the scientists cautioned that, though caffeine was a relatively safe drug, there was no indication yet about the amounts of the chemical that would act successfully against Alzheimer’s in humans. And pregnant women and people with high blood pressure should certainly avoid upping their caffeine intake.
There are several reasons why results on mice have problems translating directly to humans. When researching whether a drug works, doses on mice are sometimes much higher than anything that a doctor could safely use on a patient, even allowing for adjustments of metabolic rate and size. “Because your primary concern in the animal experiments is to demonstrate an effective treatment, you will dose higher than you would in a human,” says Dominic Wells, head of the department of cellular and molecular neuroscience at Imperial College London.
“So if you hear a story that a mouse has been cured of this or that, you need to take that with a big pinch of salt because we would almost certainly not be allowed to take the same sort of dose rate straight into a human. We’d need to make a significant reduction to test for safety before we could consider upping the dose,” he says.
Trials using animals tend to focus on a single question — efficacy or toxicity, for example. But to make something suitable for humans requires the management of side-effects, and this might take years to tackle.
In 2006, Daniel Hackam of the University of Toronto looked at how many animal-based experiments had been later verified by successful human trials. Out of 76 studies published between 1980 and 2000, 28 were successfully replicated in human randomized trials, 14 were contradicted in trials and 34 remained untested.
In a letter published in the Journal of the American Medical Association, Hackam wrote: “Patients and physicians should remain cautious about extrapolating the findings of prominent animal research to the care of human disease ... poor replication of even high-quality animal studies should be expected by those who conduct clinical research.”
There are also physiological limitations.
“We can genetically modify, by a single intramuscular injection, a whole muscle in a mouse,” Wells says. “If we try to do that in a person it just doesn’t work because the spread of the agent we inject is maybe 4 to 5 millimeters — the size of a mouse muscle.”
And in other areas, mice are not sophisticated enough to model humans.
Neurologically, “mice are wired in a different way,” Wells says. “If I showed you a blind mouse and a mouse with perfect eyesight in a cage, you wouldn’t be able to tell the difference because mice rely a lot on smell and touch.”
None of this should put a negative spin, however, on the importance of mice in research. So far, 26 Nobel prizes have gone to discoveries where research on mice has been key, including work on vitamins, the discovery of penicillin, the development of numerous vaccines and understanding the role of viruses.
The return of US president-elect Donald Trump to the White House has injected a new wave of anxiety across the Taiwan Strait. For Taiwan, an island whose very survival depends on the delicate and strategic support from the US, Trump’s election victory raises a cascade of questions and fears about what lies ahead. His approach to international relations — grounded in transactional and unpredictable policies — poses unique risks to Taiwan’s stability, economic prosperity and geopolitical standing. Trump’s first term left a complicated legacy in the region. On the one hand, his administration ramped up arms sales to Taiwan and sanctioned
World leaders are preparing themselves for a second Donald Trump presidency. Some leaders know more or less where he stands: Ukrainian President Volodymyr Zelenskiy knows that a difficult negotiation process is about to be forced on his country, and the leaders of NATO countries would be well aware of being complacent about US military support with Trump in power. Israeli Prime Minister Benjamin Netanyahu would likely be feeling relief as the constraints placed on him by the US President Joe Biden administration would finally be released. However, for President William Lai (賴清德) the calculation is not simple. Trump has surrounded himself
US president-elect Donald Trump is to return to the White House in January, but his second term would surely be different from the first. His Cabinet would not include former US secretary of state Mike Pompeo and former US national security adviser John Bolton, both outspoken supporters of Taiwan. Trump is expected to implement a transactionalist approach to Taiwan, including measures such as demanding that Taiwan pay a high “protection fee” or requiring that Taiwan’s military spending amount to at least 10 percent of its GDP. However, if the Chinese Communist Party (CCP) invades Taiwan, it is doubtful that Trump would dispatch
Taiwan Semiconductor Manufacturing Co (TSMC) has been dubbed Taiwan’s “sacred mountain.” In the past few years, it has invested in the construction of fabs in the US, Japan and Europe, and has long been a world-leading super enterprise — a source of pride for Taiwanese. However, many erroneous news reports, some part of cognitive warfare campaigns, have appeared online, intentionally spreading the false idea that TSMC is not really a Taiwanese company. It is true that TSMC depositary receipts can be purchased on the US securities market, and the proportion of foreign investment in the company is high. However, this reflects the